Guidance To Cut Diabetes Drug CV Risk Gets First Test With Pending NDAs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s flexibility in applying its new guidance for cardiovascular safety of diabetes drugs will be tested in coming months as it reviews a handful of pending NDAs and enters into discussions about other drugs in late-stage development.
You may also be interested in...
MannKind Breathes Easier After FDA Diabetes Safety Guidance
MannKind is reassuring investors that its fast-acting inhaled insulin product Afresa, due for a U.S. filing soon, is likely to satisfy new FDA guidelines for cardiovascular safety of diabetes drugs
MannKind Breathes Easier After FDA Diabetes Safety Guidance
MannKind is reassuring investors that its fast-acting inhaled insulin product Afresa, due for a U.S. filing soon, is likely to satisfy new FDA guidelines for cardiovascular safety of diabetes drugs
Vivus’ Qnexa Combo For Obesity Needs FDA ‘Persuasion’ To Take First-Line In Diabetes
CEO hails positive Phase III data, but not all analysts are convinced.